Insulin use and increased risk of mortality in type 2 diabetes: a cohort study

Aim: To compare population‐based rates of all‐cause and cardiovascular (CV) mortality in newly treated patients with type 2 diabetes according to levels of insulin exposure.

[1]  L. Rydén,et al.  Insulin‐induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study , 2009, Diabetes, obesity & metabolism.

[2]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[3]  S. Schinner.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[4]  B. Psaty,et al.  Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? , 2008, JAMA.

[5]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[6]  D. Margolis,et al.  Association between serious ischemic cardiac outcomes and medications used to treat diabetes , 2008, Pharmacoepidemiology and drug safety.

[7]  Sherry A. Martin,et al.  Cardiovascular events and insulin therapy: a retrospective cohort analysis. , 2008, Diabetes research and clinical practice.

[8]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[9]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[10]  R. Klein,et al.  Relationship of Glycemic Control, Exogenous Insulin, and C-Peptide Levels to Ischemic Heart Disease Mortality Over a 16-Year Period in People With Older-Onset Diabetes , 2008, Diabetes Care.

[11]  J. Danesh,et al.  Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. , 2007, European heart journal.

[12]  P. Beck,et al.  Health Services Databases in Saskatchewan , 2007 .

[13]  J. Gurwitz,et al.  Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. , 2006, The American journal of managed care.

[14]  W. Ray.  Observational studies of drugs and mortality. , 2005, The New England journal of medicine.

[15]  D. Grobbee,et al.  High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes? , 2005, Atherosclerosis.

[16]  D. Grobbee,et al.  Insulin treatment and cardiovascular disease; friend or foe? A point of view , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[17]  A. Aljada,et al.  The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  S. Majumdar,et al.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.

[19]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[20]  A. Folsom,et al.  Nontraditional Risk Factors for Coronary Heart Disease Incidence among Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 2000, Annals of Internal Medicine.

[21]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[22]  L. Bouter,et al.  Insulin and risk of cardiovascular disease: a meta-analysis. , 1998, Circulation.

[23]  F. Nuttall,et al.  Cardiovascular Events and Correlates in the Veterans Affairs Diabetes Feasibility Trial Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes , 1997 .

[24]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[25]  G. Slama.  The insulin sparing effect of metformin in insulin-treated diabetic patients. , 1991, Diabete & metabolisme.

[26]  A. Ziegler,et al.  Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. , 1987, Diabete & metabolisme.